0.9 C
Beijing
Wednesday, February 18, 2026

Veritas Capital Secures $14.4 Billion for Ninth Flagship Fund Amidst Market Slowdown

Veritas Capital successfully closes its ninth flagship fund at $14.4 billion, exceeding targets amidst a challenging private equity market. Learn about their investment strategy and recent successes.

MTN Group to Acquire IHS Towers in Landmark $6.2 Billion Deal

MTN Group agrees to acquire IHS Towers for $6.2 billion in an all-cash deal, strengthening its digital infrastructure across Africa. Learn about the deal's terms, shareholder premiums, and strategic implications.

Danaher to Acquire Masimo in Landmark $9.9 Billion Deal, Expanding Diagnostics Reach

Danaher is set to buy Masimo for $9.9 billion, marking a major expansion into diagnostics and patient monitoring technology in one of the industry's largest recent deals.

Semaglutide and Tirzepatide: Key Drugs for Long-Term Weight Loss and Diabetes Prevention

LifestyleHealthSemaglutide and Tirzepatide: Key Drugs for Long-Term Weight Loss and Diabetes Prevention

At 52, Kathryn Dean, a property agent from Dallas, Texas, found success in achieving long-term weight loss and preventing type-2 diabetes through the use of semaglutide and tirzepatide. After struggling with weight gain and a prediabetes diagnosis, Dean sought medical intervention to manage her condition and health.

Dean’s weight had increased from the age of 37, peaking at 79.8kg (176 pounds) by the time she was 46. Despite cutting out sugar, maintaining a vegetarian diet, and exercising regularly, she was unable to lose weight. Doctors attributed the issue to hormonal changes and age. She was diagnosed with prediabetes, a condition where blood sugar levels are elevated but not high enough to qualify as diabetes. This condition is often linked to being overweight and can progress to type-2 diabetes if untreated.

After learning about semaglutide, a drug used for type-2 diabetes and long-term weight management, Dean began her journey toward better health. In May 2023, she ordered the drug and lost 1.3kg (3 pounds) in the first month. Paired with a vitamin B12 supplement, semaglutide helped her control her appetite and metabolize fat, providing her with increased energy. Over eight months, she lost a total of 6.8kg.

Under medical guidance, Dean transitioned to tirzepatide, another FDA-approved drug used for weight loss and diabetes. Sold under the brand names Zepbound for weight loss and Mounjaro for diabetes, tirzepatide led to an additional weight loss of 11.3kg. Now weighing 61.9kg, Dean is satisfied with her progress and no longer classified as prediabetic. Her cholesterol and triglyceride levels are back within normal ranges.

Despite side effects like nausea, Dean says the drugs were life-changing, and she feels healthier and more energized. Dr. Garrett Garner, an obstetrician specializing in women’s healthcare, advises that side effects can be managed through smaller meals, upright posture after eating, and a high-fiber diet. Weight maintenance on these drugs may involve switching to monthly injections once the goal weight is reached.

For those considering these treatments, Dean recommends incorporating protein into meals, staying hydrated, and maintaining regular exercise. She believes that anyone struggling with weight loss should give these medications a try, as they may offer life-changing results just like they did for her.

READ MORE:

Check out our other content

Check out other tags:

Most Popular Articles